Faktor XII (Hageman-Faktor) Seine Rolle bei der Blutgerinnung und Fibrinolyse

C. Kluft; G. Dooijewaard

doi:10.1055/s-0038-1659869

Hämostaseologie, Table of Contents

Hamostaseologie 1988; 08(02): 102-109
DOI: 10.1055/s-0038-1659869

Originalarbeiten

Schattauer GmbH

Faktor XII (Hageman-Faktor) Seine Rolle bei der Blutgerinnung und Fibrinolyse^[*]

Authors

C. Kluft

¹Dooijewaard Gaubius Institut TNO, Leiden, Niederlande
G. Dooijewaard

¹Dooijewaard Gaubius Institut TNO, Leiden, Niederlande

Abstract

Full Text

References

Literatur
1 Agostini De A, Lijnen H.R, Pixley R.A, Colman R.W, Schapira M. Inactivation of factor XII fragment in normal plasma. Predominant role of CI-inhibitor. J Clin Invest 1984; 73: 1542-9.
2 Aznar J, Mayans J, Aznar J.A, Fernandez-Pavon A, Calabuig R. Deficiencia de factor Hageman. A proposito de un caso. Sangre 1973; 18: 356-64.
3 Botti R.E, Ratnoff O.D. Studies on the pathogenesis of thrombosis : an experimental “hypercoagulable” state induced by the intravenous injection of ellagic acid. J Lab Clin Med 1964; 64: 385-98.
4 Bouma B.N, Griffin J.H. Human blood coagulation Factor XI: purification, properties and mechanism of activation by activated Factor XII. J Biol Chem 1977; 252: 6432-7.
5 Cicardi M, Bergamaschini L, Marasini B, Boccassini G, Tucci A, Agostoni A. Hereditary angioedema: An appraisal of 104 cases. Am J Med Sci 1982; 284: 2-9.
6 Claeys H, Collen D. Purification and characterization of bovine coagulation Factor XII. (Hageman factor). Eur J Biochem 1978; 87: 69-74.
7 Cochrane C.G, Griffin J.H. The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol 1982; 33: 241-306.
8 Cool D.E, Edgell C.J, Louie G.V, Zoller M.J, Brayer G.D, MacGillivray R.T. Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XII_a . J Biol Chem 1985; 260: 13666-76.
9 Cool D.E, Mac Gillivray R.T.A. Characterization of the human blood coagulation Factor XII gene. J Biol Chem 1987; 262: 13662-73.
10 Cordova C, Violi F, Alessandri C, Ferro D, Saliola M, Balsano F. Hageman factor, high molecular weight kininogen, and pre-kallikrein in chronic liver disease. J Clin Pathol 1986; 39: 1003-5.
11 Didisheim P. Hageman factor deficiency (Hageman trait). Arch Intern Med 1962; 110: 74-81.
12 Dunn J.T, Kaplan A.P. Formation and structure of human Hageman factor fragments. J Clin Invest 1982; 70: 627-31.
13 Dunn J.T, Silverberg M, Kaplan A.P. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem 1982; 257: 1779-84.
14 Egberg N, Overmark-Berggren I. Assay for Hageman factor (factor XII) in human plasma by means of chromogenic substrate for plasma kallikrein. Thromb Res 1983; 31: 875-80.
15 Espana F, Ratnoff O.D. Activation of Hageman factor (Factor XII) by sulfatides and other agents in the absence of plasma proteases. J Lab Clin Med 1983; 102: 31-45.
16 Fujikawa K, Davie E.W. Human factor XII (Hageman factor). Methods Enzymol 1981; 80: 198-211.
17 Fujikawa K, Heimark R.L, Kurachi K, Davie E.W. Activation of bovine factor XII (Hageman factor) by plasma kallikrein. Biochemistry 1980; 19: 1322-30.
18 Fujikawa K, Kurachi K, Davie E.W. Characterization of bovine factor XII_a (activated Hageman factor). Biochemistry 1977; 16: 4182-8.
19 Fujikawa K, McMullen B.A. Amino acid sequence of human beta-factor XII_a . J Biol Chem 1983; 258: 10924-33.
20 Fujikawa K, Walsh K.A, Davie E.W. Isolation and characterization of bovine factor XII (Hageman factor). Biochemistry 1977; 16: 2270-8.
21 Gallimore M.J. Plasma-Präkallikrein. Hämostaseologie 1987; 7: 166-71.
22 Gallimore M.J, Rees W.A, Fuhrer G, Heller W. A direct chromogenic peptide substrate assay for Hageman factor (FXII). Fibrinolysis 1987; 1: 123-7.
23 Gevers Leuven J.A, Kluft C, Bertina R.M, Hessel L.W. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 1987; 109: 631-6.
24 Goodnough L.T, Saito H, Ratnoff O.D. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias : A report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 1983; 62: 248-55.
25 Gordon E.M, Donaldson V.H, Saito H, Su E, Ratnoff O.D. Reduced titers of Hageman factor (factor XII) in orientals. Ann Intern Med 1981; 95: 697-700.
26 Gordon E.M, Ratnoff O.D, Saito H, Donaldson V.H, Pensky J, Jones P.K. Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased CI esterase inhibitor titers in women taking oral contraceptives. J Lab Clin Med 1980; 96: 762-9.
27 Griep M.A, Fujikawa K, Nelsestuen G.L. Possible basis for the apparent surface selectivity of the contact activation of human blood coagulation factor XII. Biochemistry 1986; 25: 6688-94.
28 Griffin J.H. The role of surface in surface-dependent activation of Hageman Factor (Factor XII). Proc Natl Acad Sci USA 1978; 75: 1998-2002.
29 Griffin J.H, Beretta G. Molecular mechanisms of surface-dependent activation of Hageman factor. In: Kinins II. Fujii S, Moriya H, Suzuki T. (Eds) New York: Plenum; 1979: 39-51.
30 Griffin J.H, Cochrane C.G. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci USA 1976; 73: 2554-8.
31 Griffin J.H, Cochrane C.G. Recent advances in the understanding of contact activation reactions. Semin Thromb Hemostas 1979; 5: 254-73.
32 Gunzler W.A, Steffens G.J, Otting F, Kim S-MA, Frankus E, Flohe L. The primary structure of high molecular mass urokinase from human urine. Hoppe-Seylers Z Physiol Chem 1982; 363: 1155-65.
33 Haanen C, Hommes F, Benraad H, Morselt G. A case of Hageman-factor deficiency and a method to purify the factor. Thromb Diath Haemorrh 1960; 5: 201-7.
34 Harpel P.C, Cooper N.R. Studies on human plasma CI-inactivator-enzyme interactions. I. Mechanism of interaction with Cls, plasmin and trypsin. J Clin Invest 1975; 55: 593-609.
35 Hedner U. Studies on an inhibitor of plasminogen activation in human serum. Thromb Diath Haemorrh 1973; 30: 414-24.
36 Hedner U. A human inhibitor of Hageman factor acting as a fibrinolytic inhibitor. In: Protides of the Biological Fluids. Peeters H. (Ed) Oxford: Pergamon Press; 1980: 37-40.
37 Hedner U, Martinsson G. Inhibition of activated Hageman factor (factor XII_a) by an inhibitor of the plasminogen activation (PA inhibitor). Thromb Res 1970; 12: 1015-23.
38 Heimark R.L, Kurachi K, Fujikawa K, Davie E.W. Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature 1980; 286: 456-60.
39 Hojima Y, Cochrane C.G, Wiggins R.C, Austen K.F, Stevens R.L. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 1984; 63: 1453-9.
40 Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-9.
41 Ikkala E, Myllyla G, Nevanlinna H.R. Rare congenital coagulation factor defects in Finland. Scand J Haematol 1971; 8: 210-5.
42 Iwaarden Van F, Bouma B.N. Role of high molecular weight kininogen in contact activation. Semin Thromb Hemostas 1987; 13: 15-24.
43 Jespersen J, Kluft C. Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen. Levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and Cl-inactivator. Thromb Haemost 1985; 54: 454-9.
44 Kaplan A.P, Gruber B, Harpel P.C. Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-Cl-inactivator complexes by an enzyme-linked differential antibody immunosorbent assay. Blood 1985; 66: 636-41.
45 Kaplan A.P, Silverberg M. The coagula-tion-kinin pathway of human plasma. Blood 1987; 70: 1-15.
46 Klessen C, Sturzenbecher J, Markwardt F. Determination of factor XII in plasma using the kallikrein substrate chromozym PK. Thromb Res 1982; 25: 501-5.
47 Kluft C. Elimination of inhibition in euglobulin fibrinolysis by use of flufenamate. Involvement of Cl-inactivator. Haemostasis 1977; 6: 351-69.
48 Kluft C. Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein. J Lab Clin Med 1978; 91: 83-95.
49 Kluft C, Dooijewaard G, Emeis J.J. Role of the contact system in fibrinolysis. Semin Thromb Hemostas 1987; 13: 50-68.
50 Kluft C, Dooijewaard G, Emeis J.J. Contact product formation: balanced activation of coagulation and fibrinolysis. In: Enzyme Activation in Blood-Perfused Artificial Organs. Schmid-Schönbein H, Wurzinger L.J, Zimmerman R.E. (eds) Boston/Dordrecht: Martinus Nijhoff; 1985: 9-31.
51 Kluft C, Preston F.E, Malia R.G, Bertina R.M, Wijngaards G, Greaves M, Verhei-jen J.H, Dooijewaard G. Stanozolol-in-duced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemost 1984; 51: 157-64.
52 Kluft C, Svendsen L, Los P. Direct assay of factor XII_a in plasma with synthetic chromogenic substrates. Adv Exp Med Biol 1983; 156: 201-4.
53 Kurachi K, Fujikawa K, Davie E.W. Mechanism of activation of bovine factor XI by factor XII and factor XII_a . Biochemistry 1980; 19: 1330-8.
54 Laemmle B, Berrettini M, Griffin J.H. Immunoblotting studies of coagulation factor XII, plasma prekallikrein, and high molecular weight kininogen. Semin Thromb Hemostas 1987; 13: 106-14.
55 Laemmle B, Tran T.H, Duckert F. Assay of factor XII clotting activitiy in heparini-zed plasma. Am J Clin Pathol 1983; 80: 414-7.
56 Mannhalter C.h. Biochemical and functional properties of factor XI and prekallikrein. Semin Thromb Hemostas 1987; 13: 25-35.
57 Mannhalter C.h. Hochmolekulares Kininogen: Biochemie und Funktion. Hämostaseologie 1987; 7: 128-38.
58 Mannhalter C, Fischer M, Hopmeier P, Deutsch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1: 259-63.
59 Margolis J. Initiation of blood coagulation by glass and related surfaces. J Physiol (Lond) 1957; 137: 95.
60 McMillin C.R, Saito H, Ratnoff O.D, Walton A.G. The secondary structure of human Hageman factor (factor XII) and its alteration by activating agents. J Clin Invest 1974; 54: 1312-22.
61 McMullen B.A, Fujikawa K. Amino acid sequence of the heavy chain of human alpha-factor XII_a (activated Hageman factor). J Biol Chem 1985; 260: 5328-41.
62 Miles L.A, Greengard J.S, Griffin J.H. A comparison of the abilities of plasma kallikrein, factor XII_a, factor XI_a and urokinase to activate plasminogen. Thromb Res 1983; 29: 407-17.
63 Niewiarowski S, Prou-Wartelle O. Role du facteur contact (facteur Hageman) dans la fibrinolyse. Thromb Diath Haemorrh 1959; 3: 593-603.
64 Nilsson T, Bäck O. Elevated plasmin-α₂-antiplasmin complex levels in hereditary angioedema: evidence for the in vivo efficiency of the intrinsic fibrinolytic system. Thromb Res 1985; 40: 817-21.
65 Nuijens J.H, Huijbregts C.C.M, Cohen M, Navis G.O, de Vries A, Eerenberg A.J.M, Bakker J.C, Hack C.E. Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-Cl-inhibitor and kallikrein-Cl-inhibitor complexes by specific radioimmunoassays. Thromb Haemost 1987; 58: 778-85.
66 Ny T, Elgh F, Lund B. The structure of human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci USA 1984; 81: 5355-9.
67 Oh-Ishi S. Activation of factor XII in several congenitally deficient plasmas. Some aspects of activators dependent or independent of HMW-kininogen and prekalli-krein. Agents Actions 1982; (Suppl) 9: 26-30.
68 Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 1985; 41: 657-63.
69 Patthy L. Evolution of plasminogen activators. EMBO Workshop on Plasminogen Activation. Amalfy, Italy, Oct. 1985.
70 Pennica D, Holmes W.E, Kohr W.J, Harkins R.N, Vehar G.A, Ward C.A, Bennet W.F, Yelverton E, Seeburg P.H, Heyneker H.L, Goeddel D.V, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E.coli. Nature 1983; 301: 214-21.
71 Petersen T.E, Thogersen H.C, Skorsten-gaard K, Vibe-Pedersen K, Sahl P, Suttrup-Jensen L, Magnusson S. Partial primary structure of bovine plasma fibronec-tin: Three types of internal homology. Proc Natl Acad Sci USA 1983; 80: 137-41.
72 Pixley R.A, Schapira M, Colman R.W. The regulation of human factor XII_a by plasma proteinase inhibitors. J Biol Chem 1985; 260: 1723-9.
73 Pixley R.A, Schapira M, Colman R.W. Effect of heparin on the inactivation rate of human activated factor XII by antithrombin III. Blood 1985; 66: 198-203.
74 Que B.G, Davie E.W. Characterization of a cDNA coding for human factor XII. Biochemistry 1986; 25: 1525-8.
75 Radcliffe R, Bagdasarian A, Colman R, Nemerson Y. Activation of bovine factor VII by Hageman factor fragments. Blood 1977; 50: 611-7.
76 Ratnoff O.D. A quarter century with Mr. Hageman. Thromb Haemost 1980; 43: 95-8.
77 Ratnoff O.D, Colopy J.E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602-13.
78 Ratnoff O.D, Crum J.D. Activation of Hageman factor by solutions of ellagic acid. J Lab Clin Med 1964; 63: 359-77.
79 Ratnoff O.D, Saito H. Amidolytic properties of single-chain activated Hageman factor. Proc Natl Acad Sci USA 1979; 76: 1461-3.
80 Ratnoff O.D, Saito H. The evolution of clot-promoting and amidolytic activities in mixtures of Hageman factor (factor XII) and ellagic acid. The enhancing effect of other proteins. J Lab Clin Med 1982; 100: 248-60.
81 Revak S.D, Cochrane C.G. The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule. J Clin Invest 1976; 57: 852-60.
82 Revak S.D, Cochrane C.G, Johnston A.R, Hugh T.E. Structural changes accompanying enzymatic activation of human Hageman factor. J Clin Invest 1974; 54: 619-27.
83 Saito H. Contact factors in health and disease. Semin Thromb Hemostas 1987; 13: 36-49.
84 Saito H, Hamilton S.M, Tavill A.S, Good-nough L.T, Louis L, Angeli A. Synthesis and release of Hageman factor (factor XII) by the isolated perfused rat liver. J Clin Invest 1983; 72: 948-54.
85 Saito H, Ratnoff O.D, Pensky J. Radioimmunoassay of human Hageman factor (factor XII). J Lab Clin Med 1976; 88: 506-14.
86 Schapira M. Major inhibitors of the contact phase coagulation factors. Semin Thromb Hemostas 1987; 13: 69-78.
87 Schleuning W.D. The plasminogen activators in pooled human plasma. In: Progress in Fibrinolysis, Vol VI. Davidson J.F, Bachmann F, Bouvier C.A, Kruithof E.K.O. (eds) Edinburgh: Churchill Livingstone; 1983: 39-42.
88 Shimada T, Kato H, Iwanaga S, Iwamori M, Nagai Y. Activation of factor XII and prekallikrein with cholesterol sulphate. Thromb Res 1985; 38: 21-31.
89 Silverberg M, Dunn J.T, Garen L, Kaplan A.P. Auto activation of human Hageman factor. Demonstration utilizing a synthetic substrate. J Biol Chem 1980; 255: 7281-6.
90 Silverberg M, Kaplan A.P. Enzymatic activities of activated and zymogen forms of human Hageman factor (Factor XII). Blood 1982; 60: 64-70.
91 Silverberg M, Nicoli J.E, Kaplan A.P. The mechanism by which the light chain of cleaved HMW-kininogen augments the activation of prekallikrein, Factor XI and Hageman factor. Thromb Res 1980; 20: 173-89.
92 Tankersley D.L, Alving B.M, Finlayson J.S. Activation of factor XII by dextran sulfate: the basis for an assay of factor XII. Blood 1983; 62: 448-56.
93 Tans G, Rosing J. Structural and functional characterization of Factor XII. Semin Thromb Hemostas 1987; 13: 1-14.
94 Tans G, Rosing J, Griffin J.H. Sulfatide-dependent autoactivation of human blood coagulation Factor XII (Hageman factor). J Biol Chem 1983; 258: 8215-22.
95 Tripode M, Citarella F, Guida S, Galeffi P, Gallo E, Ferrazza P, Amicone L, Mariani R, Longobardi C, Fantoni A. Molecular studies on DNA sequences coding for factor VII and factor XII of human coagulation. Ital J Biochem 1986; 35: 328-32.
96 Tsuruta J, Yamamoto T, Kambara T. Immunohistochemical studies on synthesis and distribution of Hageman factor and kininogen. Adv Exp Med Biol 1986; 198, PtB: 63-70.
97 Vinazzer H. Assay of total factor XII and of activated factor XII in plasma with a chromogenic substrate. Thromb Res 1979; 14: 155-66.
98 Verheyen J.H, Caspers M.P.M, Chang G.T.G, Pouwels P.H, Enger-Valk B.E. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. The EMBO Journal 1986; 5: 3525-30.
99 Vroman L. The importance of surfaces in contact phase reactions. Semin Thromb Hemostas 1987; 13: 79-85.
100 Walsh P.N. Platelet-mediated trigger mechanisms in the contact phase of blood coagulation. Semin Thromb Hemostas 1987; 13: 86-94.
101 Walshe K.J, Mackie I.J, Gallimore M, Machin S.J. A microtiter chromogenic substrate assay for factor XII. Thromb Res 1987; 365-71.
102 Weerasinghe K.M, Scully M.F, Kakkar V.V. Inhibition of the cerebroside sulphate (sulphatide)-induced contact activation reactions by platelet factor four. Thromb Res 1984; 33: 625-31.
103 Weiss H.J, Turitto V.T, Vivic W.J, Baumgartner H.R. Fibrin formation, fi-brinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency. Blood 1984; 63: 1004-14.
104 Wiggins R.C, Bouma B.N, Cochrane C.G, Griffin J.H. Role of high molecular weight kininogen in surface-binding and activation of coagulation factor XI and prekallikrein. Proc Natl Acad Sci USA 1977; 74: 4636-40.
105 Wiggins R.C, Cochrane C.G. The autoactivation of rabbit Hageman factor. J Exp Med 1979; 150: 1122-33.
106 Yamada K.M. Cell surface interactions with extracellular materials. Ann Rev Biochem 1983; 52: 761-99.
107 Yoshikawa I, Sakata M, Takamiya O. Determination of factor XII by functional assay with fluorogenic substrate and enzyme immunoassay. Acta Haematol Japonica 1985; 48: 176-87.
108 Zonneveld AJ van, Veerman H, Panne-koek H. Autonomous functions of structural domains of human tissue-type plasminogen activator. Proc Natl Acad Sci USA 1986; 83: 4670-4.

Faktor XII (Hageman-Faktor) Seine Rolle bei der Blutgerinnung und Fibrinolyse[*]

Authors

Faktor XII (Hageman-Faktor) Seine Rolle bei der Blutgerinnung und Fibrinolyse^[*]